European collaborative trial – an alternative method to animal experiments for the safety testing of tetanus vaccines
An in-vitro method developed by the Paul-Ehrlich-Institut for the safety testing of tetanus vaccines is entering an important phase on the way to making animal experiments permanently superfluous for this test. This week the EDQM is providing materials to control laboratories and vaccine manufacturers in 14 countries with the purpose of evaluating this in-vitro method in a European collaborative trial.
3. PEI-DKTK-Workshop – focus on innovative cancer therapies
Adoptive immune therapy using CAR and TCR T-cells presents an innovative therapy approach for treatment of cancer diseases. Impressive successes were obtained in clinical trials, especially in leukaemia, with this form of treatment. Around 100 experts of the DKTK, the authorities of the länder (federal German states) and the Paul-Ehrlich-Institut exchanged their ideas at the workshop.
Mobilization of jumping genes in pluripotent stem cells may affect safety of stem cell-based therapies
Reprogramming of human cells into induced pluripotent stem cells (hiPSCs) activates normally repressed, endogenous mobile DNA (retrotransposons; jumping genes), which can result in new insertions in the stem cell genome. The function of differentiated cells derived from such stem cells could be hampered by these mutations. Moreover, these retrotransposon insertions can affect genes relevant to tumor development.